

## Lettera di intenti

Cari colleghi,

Negli ultimi due anni come membro del Consiglio direttivo di IG-IBD, ho avuto l'opportunità di contribuire attivamente alla crescita della nostra società scientifica, lavorando con dedizione per promuovere la collaborazione, il confronto e l'impegno comune. Credo fermamente che, attraverso il dialogo e il lavoro di squadra, si possano raggiungere risultati importanti. Per questo motivo, sono lieta di ripresentare la mia candidatura al Consiglio direttivo, con l'obiettivo di proseguire e consolidare i progetti che abbiamo avviato insieme e di continuare a portare il mio contributo allo sviluppo della società.

Il mio impegno per il prossimo mandato si fonda sui seguenti punti programmatici, che ho già iniziato a promuovere e che desidero ampliare:

1) Promuovere la formazione con modalità innovative: Continuare l'organizzazione di master e corsi formativi specifici in ambito clinico, endoscopico ed ecografico, nonché sulla lettura e interpretazione di dati scientifici e la creazione di protocolli di ricerca.

2) Favorire la ricerca scientifica multicentrica: Continuare a incoraggiare le idee e il contributo dei giovani specialisti, valorizzando il loro impegno e promuovendo la collaborazione tra i soci della nostra società.

3) Rafforzare la collaborazione tra IG-IBD e altre società scientifiche italiane: Promuovere una gestione sempre più multidisciplinare dei pazienti affetti da IBD e da malattie immuno-mediate concomitanti, attraverso eventi formativi e studi scientifici condivisi.

4) Espandere le collaborazioni internazionali: Proseguire e intensificare i rapporti con società scientifiche internazionali, sia europee che extraeuropee, al fine di migliorare la nostra rete di conoscenze e di esperienze.

5) Aumentare le opportunità di formazione per giovani specialisti: Continuare a promuovere borse di studio per specializzandi, giovani specialisti e altre figure professionali (biologi, nutrizionisti), incentivandone la partecipazione agli eventi formativi organizzati dalla società.

6) Migliorare la comunicazione interna tra il Consiglio direttivo e i soci: Promuovere una maggiore trasparenza e dialogo continuo, favorendo una partecipazione attiva dei soci alle attività della società.

7) Rafforzare il ruolo della società come interlocutore tecnico e scientifico con le istituzioni: Continuare a consolidare IG-IBD come punto di riferimento per le istituzioni, sia a livello nazionale che internazionale.

Con il vostro supporto, sono pronta a continuare il percorso iniziato, lavorando con entusiasmo e dedizione per la crescita e il successo della nostra comunità scientifica. Vi chiedo quindi il vostro voto di fiducia per poter proseguire su questa strada e realizzare gli obiettivi prefissati.



Milano, 26/10/2024

# CURRICULUM VITAE DR. CRISTINA BEZZIO

Name	CRISTINA
Surname	BEZZIO
Address	Via Filelfo 7, Milan 20145, Italy
E-mail	bezzioc@gmail.com – Cristina.bezzio@hunimed.eu
Nationality	Italian
Date of birth	12.08.1981

BZZCST81M52C933G

## WORK EXPERIENCE

- |   |   |
|---|---|
| <ul style="list-style-type: none"><li>• Date</li><li>• Name and address of employer</li><li>• Type of business or sector</li><li>• Main activities and responsibilities</li></ul> | <p>October 2023 – present<br/>IBD Center, Humanitas Research Hospital, Rozzano (Milan, Italy)</p> <p>Gastroenterologist (M.D., Ph.D.), researcher</p> <ul style="list-style-type: none"><li>- Managing patients with inflammatory bowel diseases, including prescription of biological medications, intestinal ultrasound, and diagnostic and operative endoscopy.</li><li>- Inpatient care and outpatient clinics at the Department of Gastroenterology and Digestive Endoscopy Conducting clinical research, including the management of international experimental scientific protocols and collaborative studies.</li><li>- Teaching activities</li><li>- Clinical Research activity</li><li>- Providing intestinal ultrasound teaching in collaboration with the International Bowel Ultrasound Group (IBUS) and Italian Society of Ultrasound in Medicine and Biology (SIUMB), in conjunction with the ultrasound school of ASST Fatebenefratelli Sacco in Milan.</li></ul> |
| <ul style="list-style-type: none"><li>• Date</li><li>• Name and address of employer</li><li>• Type of business or sector</li><li>• Main activities and responsibilities</li></ul> | <p>September 2015 – September 2023<br/>ASST Rhodense Hospital (Milan, Italy)</p> <p>Gastroenterologist (M.D., Ph.D.)</p> <ul style="list-style-type: none"><li>- Inpatient care and outpatient clinics at the Department of Gastroenterology and Digestive Endoscopy</li><li>- Managing patients with inflammatory bowel diseases, including prescription of biological medications, intestinal ultrasound, and diagnostic and operative endoscopy.</li><li>- Conducting clinical research, including the management of international experimental scientific protocols and collaborative studies.</li><li>- Teaching activities as an adjunct professor at the University of Pavia.</li><li>- Providing intestinal ultrasound teaching in collaboration with the International Bowel Ultrasound Group (IBUS) and Italian Society of Ultrasound in Medicine and Biology</li></ul>   |

(SIUMB), in conjunction with the ultrasound school of ASST Fatebenefratelli Sacco in Milan.

- Date | October 2012 - September 2015
- Name and address of employer | Unit of Gastroenterology - Luigi Sacco Hospital, Università degli studi di Milano  
Gastroenterologist

## EDUCATION AND TRAINING

- Date | 08/FEB/2022

**National Scientific Qualification as Associate Professor in the competitive sector 06/D4 Dermatological Diseases, Infectious Diseases, and Digestive System Diseases.**

- Dates | 30/OCT/2016- 1/JAN/2018
- Name and type of organisation providing education and training | Humanitas University, Milan, Italy
- Title of qualification awarded | **Second-level university master's degree in hepatobiliary pancreatic endoscopy ultrasound and endoscopy**
- Principal subjects/occupational skills covered | Theoretical and practical activities in hepatobiliary pancreatic endoscopy ultrasound

- Dates | 31/OCT/2012- 31/JAN/2016
- Name and type of organisation providing education and training | Unit of Gastroenterology - Luigi Sacco Hospital, Università degli studi di Milano
- Title of qualification awarded | Gastroenterology Unit  
**Ph.D. in Gastroenterology**
- Principal subjects/occupational skills covered | Clinical and basic research, management of experimental scientific protocols, speaker at national and international conferences, collaboration with national and international research groups in the field of chronic inflammatory bowel diseases

- Dates | 16/MAY/2015
- Name and type of organisation providing education and training | SIUMB (Italian Society of Ultrasound in Medicine and Biology)
- Title of qualification awarded | **Ultrasound Proficiency Course**  
*SIUMB National Proficiency Diploma.*

- Dates | *Academic years: 2006/2007 - 2010/2011*
- Name and type of organisation providing education and training | **University of Milan - Specialization in Gastroenterology**
- Title of qualification awarded | Thesis: "Real-time sonoelastography in determining fibrosis in stenosing Crohn's disease"  
**Gastroenterologist**

<ul style="list-style-type: none"> <li>• Dates</li> <li>• Name and type of organisation providing education and training</li> <li>Title of qualification awarded</li> </ul>	<p>26/FEB2007</p> <p>University of Milan - Faculty of Medicine and Surgery</p> <p><b>State examination for the qualification to practice as a medical surgeon</b></p> <p><b>Qualification to practice the profession (score of 270/270).</b></p>
<ul style="list-style-type: none"> <li>• Dates</li> <li>• Name and type of organisation providing education and training</li> <li>Title of qualification awarded</li> </ul>	<p><i>Academic years: 2000/2001 - 2005/2006</i></p> <p>University of Milan - Faculty of Medicine and Surgery</p> <p><b>Bachelor's degree in medicine and surgery</b></p>
<ul style="list-style-type: none"> <li>• Principal subjects/occupational skills covered</li> </ul>	<p>Thesis: "Perfusional echoangiography in the differential diagnosis of inflammatory masses and intra-abdominal abscesses in Crohn's disease"</p>

## SKILLS AND COMPETENCES, AND RESEARCH AND TEACHING ACTIVITIES

<b>CLINICAL ACTIVITY</b>	Inpatient care, gastroenterology and endoscopy outpatient clinics. After completing a specialization in gastroenterology: management of the tertiary level outpatient clinic for IBD, prescription of biological drugs, intestinal ultrasound clinic, diagnostic and operative endoscopy
<b>AREAS OF SCIENTIFIC RESEARCH</b>	Research primarily focused on inflammatory bowel diseases and intestinal ultrasound. Coordinator and co-coordinator of over 30 phase II, III, and IV studies in the field of drugs for the treatment of chronic inflammatory bowel diseases, in collaboration with national and international research groups
<b>TEACHING ACTIVITY</b>	Teaching activities as an adjunct professor at the School of Specialization in Gastroenterology of the University of Pavia from the academic year 2019-2020 to the academic year 2021-2022. Teaching activities in intestinal ultrasound with the International Bowel Ultrasound Group (IBUS) and Italian Society of Ultrasound in Medicine and Biology (SIUMB)
	Involved as a lecture, speaker, tutor, and moderator in over 100 national and international educational events
<b>AFFILIATION</b>	<ul style="list-style-type: none"> <li>- IBUS (International Bowel Ultrasound Group)</li> <li>- Board of Directors of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) since December 2022</li> <li>- European Crohn's and Colitis Organization (ECCO)</li> <li>- SIUMB (Italian Society of Ultrasound in Medicine and Biology)</li> </ul>

**EDITOR/ REVIEWER****Associate editor of Digestive and Liver Disease (Section Imaging)****Reviewer for Lancet Gastroenterology and Hepatology, Clinical Gastroenterology and Hepatology, Inflammatory Bowel Disease, Digestive and Liver Disease, Therapeutic Advances in Gastroenterology and Expert Opinion on Biological Therapy****PUBLICATIONS****H-index, 20 (Scopus, 04.04.2024)****PUBLICATIONS**

1. Privitera G, Bezzio C, Dal Buono A, Gabbiadini R, Loy L, Brandaleone L, Marcozzi G, Migliorisi G, Armuzzi A. How comparative studies can inform treatment decisions for Crohn's disease. *Expert Opin Biol Ther*. 2024 Aug 12;1-18. doi: 10.1080/14712598.2024.2389985. Epub ahead of print. PMID: 39132872.
2. Migliorisi G, Mastrorocco E, Dal Buono A, Gabbiadini R, Pellegatta G, Spaggiari P, Racca F, Heffler E, Savarino EV, Bezzio C, Repici A, Armuzzi A. Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review. *J Clin Med*. 2024 Jul 14;13(14):4119. doi: 10.3390/jcm13144119. PMID: 39064159; PMCID: PMC11278413.
3. Bonifacio C, Dal Buono A, Levi R, Gabbiadini R, Reca C, Bezzio C, Francone M, Armuzzi A, Balzarini L. Reporting of Magnetic Resonance Enterography in Inflammatory Bowel Disease: Results of an Italian Survey. *J Clin Med*. 2024 Jul 5;13(13):3953. doi: 10.3390/jcm13133953. PMID: 38999518; PMCID: PMC11242042.
4. D'Amico F, Massimino L, Palmieri G, Dal Buono A, Gabbiadini R, Caron B, Moreira P, Silva I, Bosca-Watts M, Innocenti T, Dragoni G, Bezzio C, Zilli A, Furfaro F, Saibeni S, Chaparro M, García MJ, Michalopoulos G, Viazis N, Mantzaris GJ, Ellul P, Gisbert JP, Magro F, Peyrin-Biroulet L, Armuzzi A, Ungaro F, Danese S, Fiorino G, Allocca M. An international multicentre study of SwiTching from Intravenous to subcutaneous infliximab and vedolizumab in inflammatory bowel diseases: The TIME study. *Eur J Clin Invest*. 2024 Jul 9:e14283. doi: 10.1111/eci.14283. Epub ahead of print. PMID: 38979834.
5. Maconi G, Lepore F, Saleh A, Saibeni S, Bezzio C, Cheli S, Massari A, Gridavilla D, Ferretti F, Cannatelli R, Ardizzone S, Clementi E, Abraham B. Factors correlated with transmural healing in patients with Crohn's disease in long-term clinical remission on anti-TNF medication. *Dig Liver Dis*. 2024 Jun 18:S1590-8658(24)00784-9. doi: 10.1016/j.dld.2024.05.026. Epub ahead of print. PMID: 38897858.
6. De Deo D, Dal Buono A, Gabbiadini R, Spaggiari P, Busacca A, Masoni B, Ferretti S, Bezzio C, Armuzzi A. Management of proctitis in ulcerative colitis and the place of biological therapies. *Expert Opin Biol Ther*. 2024 Jun;24(6):443-453. doi: 10.1080/14712598.2024.2369189. Epub 2024 Jun 17. PMID: 38874980.
7. Loy L, Petronio L, Marcozzi G, Bezzio C, Armuzzi A. Dietary Fiber in Inflammatory Bowel Disease: Are We Ready to Change the Paradigm? *Nutrients*. 2024 Apr 10;16(8):1108. doi: 10.3390/nu16081108. PMID: 38674799; PMCID: PMC11053563.
8. Spertino M, Gabbiadini R, Dal Buono A, Busacca A, Franchellucci G, Migliorisi G, Repici A, Spinelli A, Bezzio C, Armuzzi A. Management of Post-Operative Crohn's Disease: Knowns and Unknowns. *J Clin Med*. 2024 Apr 16;13(8):2300. doi: 10.3390/jcm13082300. PMID: 38673573; PMCID: PMC11051270.
9. Vernerio M, Bezzio C, Ribaldone DG, Caprioli FA, Fantini MC, Festa S, Macaluso FS, Orlando A, Pugliese D, Renna S, Rispo A, Savarino EV, Variola A, Saibeni S; Italian Group for Inflammatory Bowel Disease (IG-IBD). Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey. *J Clin Med*. 2024 Mar 23;13(7):1857. doi: 10.3390/jcm13071857. PMID: 38610623; PMCID: PMC11012957.
10. Macaluso FS, Caprioli F, Benedan L, Bezzio C, Caporali R, Cauli A, Chimenti MS, Ciccia F, D'Angelo S, Fantini MC, Festa S, Iannone F, Lubrano E, Mariani P, Papi C, Provenzano G, Pugliese D, Rispo A, Saibeni S,

- Salvarani C, Variola A, Zenga M, Armuzzi A, Orlando A, Gerli R. The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus. *Autoimmun Rev.* 2024 Mar 22;23(5):103533. doi: 10.1016/j.autrev.2024.103533. Epub ahead of print. PMID: 38521214.
11. Vernero M, Saibeni S, Scalvini D, Cicalini C, Chiarello L, Nardi S, Ribaldone DG, Bezzio C. Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational Study. *J Clin Med.* 2024 Feb 9;13(4):1019. doi: 10.3390/jcm13041019. PMID: 38398332; PMCID: PMC10889244.
  12. Bezzio C, Saibeni S, Vernero M, Furfaro F, Monteleone M, Ribaldone D, Fiorino G, Friedman AB, Armuzzi A, Scalvini D, Maconi G. The learning curve for using intestinal ultrasonography. *Dig Liver Dis.* 2024 Feb 5:S1590-8658(24)00222-6. doi: 10.1016/j.dld.2024.01.192. Epub ahead of print. PMID: 38320914.
  13. Dragoni G, Innocenti T, Amiot A, Castiglione F, Melotti L, Festa S, Savarino EV, Truyens M, Argyriou K, Noviello D, Molnar T, Bouillon V, Bezzio C, Eder P, Fernandes S, Kagramanova A, Armuzzi A, Oliveira R, Viola A, Ribaldone DG, Drygiannakis I, Viganò C, Calella F, Gravina AG, Pugliese D, Chaparro M, Ellul P, Vieujean S, Milla M, Caprioli F; "TOFA-poSTOP" Study Group. Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study. *Am J Gastroenterol.* 2024 Mar 19. doi: 10.14309/ajg.0000000000002676. Epub ahead of print. PMID: 38305302.
  14. Bergamaschi G, Castiglione F, D'Inca R, Astegiano M, Fries W, Milla M, Ciacci C, Rizzello F, Saibeni S, Ciccocioppo R, Orlando A, Bossa F, Principi M, Vernia P, Ricci C, Scribano ML, Bodini G, Mazzucco D, Bassotti G, Riegler G, Buda A, Neri M, Caprioli F, Monica F, Manca A, Villa E, Fiorino G, Aronico N, Lenti MV, Mengoli C, Testa A, Vecchi M, Klersy C, Di Sabatino A; RIDART I investigators. Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD). *Dig Liver Dis.* 2024 Jan 30:S1590-8658(24)00193-2. doi: 10.1016/j.dld.2024.01.176. Epub ahead of print. PMID: 38296690.
  15. Migliorisi G, Vella G, Dal Buono A, Gabbiadini R, Busacca A, Loy L, Bezzio C, Vinciguerra P, Armuzzi A. Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It. *Cells.* 2024 Jan 12;13(2):142. doi: 10.3390/cells13020142. PMID: 38247834; PMCID: PMC10814681.
  16. Pugliese N, Giuli L, Mastrorocco E, Santopaolo F, Marcozzi G, Bezzio C, Buono AD, Gabbiadini R, Gasbarrini A, Ponziani FR, Armuzzi A, Aghemo A. Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease - A comprehensive narrative review. *Dig Liver Dis.* 2023 Dec 2:S1590-8658(23)01039-3. doi: 10.1016/j.dld.2023.11.021. Epub ahead of print. PMID: 38044225.
  17. Vernero M, Bezzio C, Ribaldone DG, Costa S, Scalvini D, Tribocco E, Manes G, Saibeni S. Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease. *J Clin Med.* 2023 Oct 29;12(21):6839. doi: 10.3390/jcm12216839. PMID: 37959304; PMCID: PMC10647534.
  18. Cavalli CAM, Gabbiadini R, Dal Buono A, Quadarella A, De Marco A, Repici A, Bezzio C, Simonetta E, Aliberti S, Armuzzi A. Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections. *J Clin Med.* 2023 Oct 9;12(19):6419. doi: 10.3390/jcm12196419. PMID: 37835065; PMCID: PMC10573999.
  19. Saibeni S, Bezzio C, Bossa F, Privitera AC, Marchi S, Roselli J, Mazzuoli S, Geccherle A, Soriano A, Principi MB, Viola A, Sarpi L, Cappello M, D'Inca R, Mastronardi M, Bodini G, Guerra M, Benedetti A, Romano M, Cicala M, Di Sabatino A, Scaldaferrì F, De Rosa T, Giardino AM, Germano V, Orlando A, Armuzzi A. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study. *Dig Liver Dis.* 2023 Aug 12:S1590-8658(23)00783-1. doi: 10.1016/j.dld.2023.07.031. Epub ahead of print. PMID: 37574431.
  20. Massano A, Bertin L, Zingone F, Buda A, Visaggi P, Bertani L, de Bortoli N, Fassan M, Scarpa M, Ruffolo C, Angriman I, Bezzio C, Casini V, Ribaldone DG, Savarino EV, Barberio B. Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review. *Cancers (Basel).* 2023 Jul 27;15(15):3824. doi: 10.3390/cancers15153824. PMID: 37568640; PMCID: PMC10417189.
  21. Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábíán A, Farkas B, Katsanos K, Michalopoulos G, Ribaldone DG, Attauabi M, Zhao M, Barak HA, Yanai H, Bezzio C, Rispo A, Castiglione F, Bar-Gil Shitrit A, Pugliese D,

- Armuzzi A, Savarino EV, Kolar M, Lukáš M, Chashkova E, Filip R, Rozieres A, Nancey S, Krznarić Ž, Schäfer E, Szamosi, Sarlós P, Franko M, Drobne D, Knyazev OV, Kagramanova AV, Limdi J, Wetwittayakhleng P, Lakatos PL, Maharshak N, Bannon L, Nyári T, Szepes Z, Farkas K; TFB Study Group; Molnár T. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. *Inflamm Bowel Dis*. 2023 Aug 5;:izad135. doi: 10.1093/ibd/izad135. Epub ahead of print. PMID: 37542737.
22. Viganò C, Palermo A, Mulinacci G, Pirola L, Losco A, Meucci G, Saibeni S, Pastorelli L, Amato A, Gatti M, Cortelezzi C, Di Sabatino A, Morganti D, Boni F, Grasso G, Casella G, Casini V, Caprioli FA, Vecchi M, Bezzio C, Bergna I, Radaelli F, Mengoli C, Massironi S. Prevalence of Disease-Related Malnutrition and Micronutrients Deficit in Patients with Inflammatory Bowel Disease: A Multicentric Cross-Sectional Study by the GSMII (Inflammatory Bowel Disease Study Group). *Inflamm Bowel Dis*. 2023 Aug 3;:izad146. doi: 10.1093/ibd/izad146. Epub ahead of print. PMID: 37536282.
23. Ribaldone DG, Parisio L, Variola A, Bossa F, Castiglione F, Marzo M, Piazza N, Aratari A, Savarino EV, Bodini G, Mastronardi M, Micheli F, Mazzuoli S, Ascolani M, Viganò C, Cappello M, Bezzio C, Ciccocioppo R, Scardino G, Sarli E, Pugliese D, Scaldaferrì F, Napolitano D, Todeschini A, Geccherle A, Colaci N, Guerra M, Annese M, Testa A, Caiazzo A, Conforti FS, Festa S, Lorenzon G, Marra A, Magiotta A, Baccini F, Amato A, Poshnjari A, Vernerò M, Caprioli F, Caviglia GP; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study. *Dig Liver Dis*. 2023 Jul 19:S1590-8658(23)00763-6. doi: 10.1016/j.dld.2023.07.011. Epub ahead of print. PMID: 37474412.
24. Bezzio C, Vernerò M, Costa S, Armuzzi A, Fiorino G, Ardizzone S, Roselli J, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Alimenti E, Balestrieri P, Ricci C, Cappello M, Felice C, Coppini F, Alvisi P, Di Luna I, Gerardi V, Variola A, Mazzuoli S, Lenti MV, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)'s COVID-19 Study Group. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves. *BMC Gastroenterol*. 2023 Jul 5;23(1):230. doi: 10.1186/s12876-023-02841-0. PMID: 37407913; PMCID: PMC10324268.
25. Macaluso FS, Principi M, Facciotti F, Contaldo A, Todeschini A, Saibeni S, Bezzio C, Castiglione F, Nardone OM, Spagnuolo R, Fantini MC, Riguccio G, Conforti S, Caprioli F, Viganò C, Felice C, Fiorino G, Correale C, Bodini G, Milla M, Scardino G, Vernerò M, Desideri F, Bossa F, Guerra M, Ventimiglia M, Casà A, Rizzo G, Orlando A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study. *Inflamm Bowel Dis*. 2023 Jun 30;:izad118. doi: 10.1093/ibd/izad118. Epub ahead of print. PMID: 37390400.
26. Saibeni S, Zanetti M, Bezzio C, Pironi L, Armuzzi A, Riso S, Caprioli F, Lezo A, Macaluso FS, Pugliese D, Daperno M, Giorgetti GM; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Artificial Nutrition and Metabolism (SINPE). Nutritional care at centres managing patients with inflammatory bowel disease: A nationwide survey in Italy. *Dig Liver Dis*. 2023 Aug;55(8):1028-1033. doi: 10.1016/j.dld.2023.05.029. Epub 2023 Jun 22. PMID: 37355395.
27. Eder P, Verstock B, Culver E, Dragoni G, Kredel LI, Wypych J, de Paredes AGG, Kaniewska M, Leibovitz H, Lobaton T, Truyens M, Oracz G, Ribaldone DG, Starzyńska T, Badaoui A, Rahier JF, Bezzio C, Bossuyt P, Falloon K, Pugliese D, Frakes Vozzo C, Jess T, Larsen L, Olensen SS, Pal P, Chaparro M, Dror D, Ellul P, Gromny I, Janiak M, Maciejewska K, Peleg N, Bar-Gil Shitrit A, Szwed Ł, Talar-Wojnarowska R, Snir Y, Weissshof R, Zittan E, Miechowicz I, Goren I. Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study. *J Crohns Colitis*. 2023 Nov 24;17(11):1791-1799. doi: 10.1093/ecco-jcc/jjad097. PMID: 37283545; PMCID: PMC10673810.
28. Bezzio C, Vernerò M, Ribaldone DG, Alimenti E, Manes G, Saibeni S. Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2023 Apr 7;15(8):2197. doi: 10.3390/cancers15082197. PMID: 37190126; PMCID: PMC10136459. Dragoni G, Castiglione F, **Bezzio C**, Pugliese D, Spagnuolo R, Viola A, Cocomazzi F, Aratari A, Savarino EV, Balestrieri P, Onali S, Viganò C, Ribaldone DG, Innocenti T, Testa A, Saibeni S, Privitera G, Milla M, Armuzzi A, Fantini MC, Fiorino G. Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study. *United European Gastroenterol J*. 2023 Apr;11(3):271-281. doi: 10.1002/ueg2.12367. Epub 2023 Mar 21. PMID: 36942657; PMCID: PMC10083469.

29. Macaluso FS, Papi C, Orlando A, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. *Dig Liver Dis*. 2023 Feb 13;S1590-8658(23)00166-4. doi: 10.1016/j.dld.2023.01.155. Epub ahead of print. PMID: 36792429.
30. Yanai H, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris GJ, Mountaki K, Armuzzi A, Pugliese D, Furfaro F, Fiorino G, Drobne D, Kurent T, Yassin S, Maharshak N, Castiglione F, de Sire R, Nardone OM, Farkas K, Molnar T, Krznaric Z, Brinar M, Chashkova E, Livne Margolin M, Kopylov U, **Bezzio C**, Bar-Gil Shitrit A, Lukas M, Chaparro M, Truyens M, Nancey S, Lobaton T, Gisbert JP, Saibeni S, Bacsúr P, Bossuyt P, Schulberg J, Hoentjen F, Viganò C, Palermo A, Torres J, Revés J, Karmiris K, Velegraki M, Savarino E, Markopoulos P, Tsironi E, Ellul P, Calviño Suárez C, Weissshof R, Ben-Hur D, Naftali T, Eriksson C, Koutroubakis IE, Foteinogiannopoulou K, Limdi JK, Liu E, Suris G, Calabrese E, Zorzi F, Filip R, Ribaldone DG, Snir Y, Goren I, Banai-Eran H, Broymann Y, Amir Barak H, Avni-Biron I, Ollech JE, Dotan I, Aharoni Golan M. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. *J Crohns Colitis*. 2022 Dec 5;16(12):1882-1892. doi: 10.1093/ecco-jcc/ijac100. PMID: 35895074.
31. De Nicolò A, Cusato J, **Bezzio C**, Saibeni S, Venero M, Disabato M, Caviglia GP, Ianniello A, Manca A, D'Avolio A, Ribaldone DG. Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease. *Nutrients*. 2022 Dec 29;15(1):169. doi: 10.3390/nu15010169. PMID: 36615826; PMCID: PMC9824626.
32. Furfaro F, D'Amico F, Zilli A, Craviotto V, Aratari A, **Bezzio C**, Spinelli A, Gilardi D, Radice S, Saibeni S, Papi C, Peyrin-Biroulet L, Danese S, Fiorino G, Allocca M. Noninvasive Assessment of Postoperative Disease Recurrence in Crohn's Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol*. 2022 Dec 12;S1542-3565(22)01131-4. doi: 10.1016/j.cgh.2022.11.039. Epub ahead of print. PMID: 36521739.
33. **Bezzio C**, Alimenti E, Saibeni S. Letter: immune-mediated inflammatory diseases and inflammatory bowel disease-are we ready for a Copernican revolution? *Aliment Pharmacol Ther*. 2022 Nov;56(9):1429-1430. doi: 10.1111/apt.17235. PMID: 36221158. C
34. Cassinotti A, Mezzina N, De Silvestri A, Di Paolo D, Lenti MV, **Bezzio C**, Stradella D, Mauri M, Zadro V, Ricci C, Casini V, Radice E, Massari A, Maconi G, Saibeni S, Caprioli F, Tari R, Fichera M, Cortelezzi CC, Parravicini M, Tinelli C, Testoni PA, Pace F, Segato S, Invernizzi P, Occhipinti P, Manes G, Di Sabatino A, Pastorelli L, Vecchi M, Arduzzone S. Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study. *Eur J Gastroenterol Hepatol*. 2022 Dec 1;34(12):1238-1246. doi: 10.1097/MEG.0000000000002443.
35. Peyrin-Biroulet L, Rahier JF, Kirchgessner J, Abitbol V, Sebastian S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol*. 2022 Sep 22;S1542-3565(22)00916-8. doi: 10.1016/j.cgh.2022.09.018.
36. Macaluso FS, Principi M, Facciotti F, Contaldo A, Todeschini A, Saibeni S, **Bezzio C**, Castiglione F, Nardone OM, Spagnuolo R, Fantini MC, Riguccio G, Caprioli F, Viganò C, Felice C, Fiorino G, Correale C, Bodini G, Milla M, Scardino G, Venero M, Desideri F, Mannino M, Rizzo G, Orlando A; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study. *Dig Liver Dis*. 2022 Aug 29;S1590-8658(22)00656-9. doi: 10.1016/j.dld.2022.08.027.
37. Ferretti F, Monico MC, Cannatelli R, Carmagnola S, Lenti MV, Di Sabatino A, Conforti F, Pastorelli L, Caprioli F, **Bezzio C**, Saibeni S, Mazza S, Vecchi M, Maconi G, Arduzzone S. The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study. *Front Med (Lausanne)*. 2022 Aug



8;9:933357. doi: 10.3389/fmed.2022.933357. PMID: 36004370; PMCID: PMC9393583.

38. **Bezzio C**, Fiorino G, Ribaldone DG, Armuzzi A, Saibeni S; IG-IBD COVID-19 Study Group. IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame. *Inflamm Bowel Dis*. 2022 Aug 16;izac173. doi: 10.1093/ibd/izac173. Epub ahead of print. PMID: 35972338; PMCID: PMC9384797.
39. **Bezzio C**, Della Corte C, Venero M, Di Luna I, Manes G, Saibeni S. Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations. *Therap Adv Gastroenterol*. 2022 Jul 28;15:17562848221115312. doi: 10.1177/17562848221115312. PMID: 35924080; PMCID: PMC9340394.
40. Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, Laterza L, Viola A, Bertani L, Caprioli F, Cappello M, Barberio B, Ricci C, Balestrieri P, Daperno M, Pluchino D, Rizzello F, Scribano ML, Sablich R, Pastorelli L, Manguso F, Variola A, Di Sario A, Grossi L, Armuzzi A; IG-IBD LIVE Study Group. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. *Aliment Pharmacol Ther*. 2022 Jul;56(1):95-109. doi: 10.1111/apt.16923. Epub 2022 May 12. PMID: 35876062; PMCID: PMC9324100.
41. Kucharzik T, Wilkens R, D'Agostino MA, Maconi G, Le Bars M, Lahaye M, Bravatà I, Nazar M, Ni L, Ercole E, Allocca M, Machková N, de Voogd FAE, Palmela C, Vaughan R, Maaser C; STARDUST Intestinal Ultrasound study group. Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease. *Clin Gastroenterol Hepatol*. 2022 Jul 14:S1542-3565(22)00649-8. doi: 10.1016/j.cgh.2022.05.055. Epub ahead of print. PMID: 35842121.
42. Onali S, Pugliese D, Caprioli FA, Orlando A, Biancone L, Nardone OM, Imperatore N, Fiorino G, Cappello M, Viola A, Principi MB, **Bezzio C**, Aratari A, Carparelli S, Mazzuoli S, Manguso F, Grossi L, Bodini G, Ribaldone D, Mocchi G, Miranda A, Minerba L, Favale A, Grova M, Scucchi L, Segato S, Fries W, Castiglione F, Armuzzi A, Fantini MC; IG-IBD. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. *Am J Gastroenterol*. 2022 Aug 1;117(8):1279-1287. doi: 10.14309/ajg.0000000000001773. Epub 2022 Apr 13. PMID: 35467558.
43. Scribano ML, Aratari A, Neri B, **Bezzio C**, Balestrieri P, Baccolini V, Falasco G, Camastra C, Pantanella P, Monterubbianesi R, Tullio A, Saibeni S, Papi C, Biancone L, Cosentino R, Faggiani R. Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy. *Therap Adv Gastroenterol*. 2022 Feb 14;15:17562848211072412. doi: 10.1177/17562848211072412. PMID: 35186121; PMCID: PMC8848093.
44. Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. *Dig Liver Dis*. 2022 Apr;54(4):440-451. doi: 10.1016/j.dld.2022.01.127. Epub 2022 Feb 17. PMID: 35184989.
45. **Bezzio C**, Venero M, Ribaldone DG, Manes G, Saibeni S. Insights into the role of gastrointestinal ultrasound in ulcerative colitis. *Therap Adv Gastroenterol*. 2021 Oct 22;14:17562848211051456. doi: 10.1177/17562848211051456. PMID: 34707688; PMCID: PMC8543554.
46. **Bezzio C**, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. *Aliment Pharmacol Ther*. 2021 Dec;54(11-12):1432-1441. doi: 10.1111/apt.16663. Epub 2021 Oct 25. PMID: 34694009; PMCID: PMC8653024.
47. Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, Maida M, Soriano A, **Bezzio C**, Bodini G, Mocchiario F, Privitera AC, Simondi D, Giuffrida E, D'Inca R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group

for the Study of Inflammatory Bowel Disease (IG-IBD). Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. *Dig Liver Dis.* 2022 Mar;54(3):352-357. doi: 10.1016/j.dld.2021.08.020. Epub 2021 Sep 17. PMID: 34538764.

48. Festa S, Scribano ML, Pugliese D, **Bezzio C**, Principi M, Ribaldone DG, Allocca M, Mocci G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosentino R, Zerboni G, Aratari A, Armuzzi A, Papi C. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. *United European Gastroenterol J.* 2021 May;9(4):507-516. doi: 10.1177/2050640620977405. Epub 2021 Feb 16. PMID: 33259773; PMCID: PMC8259429.
49. M, Mandelli E, Morganti D, Omazzi B, Pellegrini L, Picascia D, Redaelli D, Reati R, Saibeni S. Inflammatory bowel disease in a colorectal cancer screening population: Diagnosis and follow-up. *Dig Liver Dis.* 2021 May;53(5):587-591. doi: 10.1016/j.dld.2020.07.036. Epub 2020 Aug 27. PMID: 32863160.
50. Manes G, **Bezzio C**, Saibeni S. Proposal for returning to routine endoscopy during the COVID-19 pandemic: what is really feasible? *Endoscopy.* 2020 Sep;52(9):815. doi: 10.1055/a-1185-9768. Epub 2020 Aug 26. PMID: 32846442.
51. Manes G, Repici A, Radaelli F, **Bezzio C**, Colombo M, Saibeni S. Planning phase two for endoscopic units in Northern Italy after the COVID-19 lockdown: An exit strategy with a lot of critical issues and a few opportunities. *Dig Liver Dis.* 2020 Aug;52(8):823-828. doi: 10.1016/j.dld.2020.05.042. Epub 2020 Jun 19. PMID: 32605868; PMCID: PMC7303656.
52. **Bezzio C**, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, Danese S, Fantini MC, Armuzzi A, Daperno M, Fiorino G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. *Gut.* 2021;69:1213-17.
53. **Bezzio C**, Saibeni S. Severe Inflammatory Bowel Disease Flares and COVID-19: Expand the Gastroenterology-Surgery Team to Include an Infectious Disease Specialist. *Gastroenterology.* 2021;160:2625-2626.
54. Privitera G, Onali S, Pugliese D, Renna S, Savarino E, Viola A, Ribaldone DG, Buda A, **Bezzio C**, Fiorino G, Fantini MC, Scaldaferrì F, Guidi L, Danese S, Gasbarrini A, Orlando A, Armuzzi A. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. *Journal of Crohn's and Colitis,* 2021, 335–339
55. **Bezzio C**, Manes G, Bini F, Pellegrini L, Saibeni S. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds. *Gut.* 2021;70:623-624. doi: 10.1136/gutjnl-2020-321760.
56. Calabrese E, Rispo A, Zorzi F, De Cristofaro E, Testa A, Costantino G, Viola A, **Bezzio C**, Ricci C, Prencipe S, Racchini C, Stefanelli G, Allocca M, Scotto di Santolo S, D'Auria MV, Balestrieri P, Ricchiuti A, Cappello M, Cavallaro F, Guarino AD, Maconi G, Spagnoli A, Monteleone G, Castiglione F. Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study. *Clin Gastroenterol Hepatol.* 2021 26:S1542-3565(21)00340-2.
57. Ardizzone S, Ferretti F, Monico MC, Carvalhas Gabrielli AM, Carmagnola S, **Bezzio C**, Saibeni S, Bosani M, Caprioli F, Mazza S, Casini V, Cortelezzi CC, Parravicini M, Cassinotti A, Cosimo P, Indriolo A, Di Sabatino A, Lenti MV, Pastorelli L, Conforti F, Ricci C, Sarzi-Puttini P, Vecchi M, Maconi G. Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. *J Gastroenterol Hepatol.* 2021 Jun 23.
58. Maconi G, Bosetti C, De Monti A, Boyapati RK, Shelton E, Piazza N, Carvalhas Gabrielli AM, Lenti MV, **Bezzio C**, Ricci C, Greco S, Romeo S, Giangregorio F, Gridavilla D, Tagliani F, Massari A, Pastorelli L, Di Sabatino A, Saibeni S, Alicante S, Ferretti F, Rizzardini G, Galli M, Ardizzone S. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. *Dig Liver Dis.* 2021;53:263-270. doi:

59. de Nucci G, Reati R, Arena I, **Bezzio C**, Devani M, Corte CD, Morganti D, Mandelli ED, Omazzi B, Redaelli D, Saibeni S, Dinelli M, Manes G. Efficacy of a novel self-assembling peptide hemostatic gel as rescue therapy for refractory acute gastrointestinal bleeding. *Endoscopy*. 2020;52:773-779. doi: 10.1055/a-1145-3412.
60. Fantini MC, Biancone L, Dragoni G, **Bezzio C**, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocchi G, Soriano A, Guglielmi FW, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Di Ruscio M, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Saibeni S, Fiorino G. Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. *Inflamm Bowel Dis*. 2020 23;26:e134-e136.
61. **Bezzio C**, Saibeni S. Gastrointestinal ultrasound in inflammatory bowel disease: Seeing beyond limits. *Dig Liver Dis*. 2020 Jan;52(1):19-20. doi: 10.1016/j.dld.2019.11.007.
62. Zadro V, Santus P, **Bezzio C**. Ulcerative Colitis: Not Only Gut. *J Crohns Colitis*. 2020 7;14:1178-1179.
63. Saibeni S, Scucchi L, Dragoni G, **Bezzio C**, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocchi G, Soriano A, Mazzuoli S, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Ruscio MD, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Fantini MC, Fiorino G; IG-IBD (Italian Group for the study of Inflammatory Bowel Disease). Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. *United European Gastroenterol J*. 2020;8:1228-1235. doi: 10.1177/2050640620964132.
64. Pastorelli L, **Bezzio C**, Saibeni S Hold the Foam: Why Topical Budesonide Remains Relevant for IBD Therapy. *Dig Dis Sci*. 2020;65:3066-3068.
65. Furfaro F, **Bezzio C**, Maconi G. Protein-losing enteropathy in inflammatory bowel diseases. *Minerva Gastroenterol Dietol*. 2015;61:261-5.
66. Schettino M, Pellegrini L, Picascia D, Saibeni S, **Bezzio C**, Bini F, Omazzi BF, Devani M, Arena I, Bongiovanni M, Manes G, Della Corte CMR. Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: A Single-Center Cohort Study.. *Am J Gastroenterol*. 2021 1;116:306-310.
67. **Bezzio C**, Pellegrini L, Manes G, Arena I, Picascia D, Della Corte C, Devani M, Schettino M, Saibeni S. Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2020 18;26. e107-e109.
68. Maconi G, Mezzina N, Landi S, Grillo S, **Bezzio C**, Bosani M, Pastorelli L, Dell'Era A, Chibbar R, Carmagnola S, Molteni P, Cassinotti A, Massari A, Ardizzone S. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience. *United European Gastroenterol J*. 2019;7:1164-1170.
69. **Bezzio C**, Festa S, Zerboni G, Papi C, Manes G, Saibeni S. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. *Expert Opin Drug Saf*. 2018;17:437-444.
70. Tontini GE, Rimondi A, Vernerio M, Neumann H, Vecchi M, Cavallaro F and **Bezzio C**. Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons. *Therap Adv Gastroenterol*. 2021.10;14: 17562848211017730.
71. Schettino M, Saibeni S, **Bezzio C**, de Nucci G, Manes G. Efficacy, safety and tolerability, the imperfect triangle arising from the new low volume colon preparations. *Dig Liver Dis*. 2020;52:840-841.
72. Manes G, Saibeni S, Pellegrini L, Picascia D, Pace F, Schettino M, **Bezzio C**, de Nucci G, Hassan C, Repici

A; and The Fast-Track Endoscopy Study Group. Improvement in appropriateness and diagnostic yield of fast-track endoscopy during the COVID-19 pandemic in Northern Italy. *Endoscopy*. 2021;53:162-165.

73. de Nucci G, Imperatore N, Picascia D, Mandelli ED, **Bezzio C**, Arena I, Omazzi B, Larghi A, Manes G. Endoscopic ultrasound-guided gallbladder drainage in pancreatic cancer and cholangitis: A case report. *World J Gastrointest Endosc*. 2020 16;12: 488-492
74. Delconte G, Cavalcoli F, Magarotto A, Centonze G, **Bezzio C**, Cattaneo L, Rausa E, Kelly ME, Bonitta G, Milione M, Enzo M. Does ProCore Fine-Needle Biopsy Really Improve the Clinical Outcome of Endoscopic Ultrasound-Guided Sampling of Pancreatic Masses? *Dig Dis*. 2022;40(1):78-84. doi: 10.1159/000516177. Epub 2021 Mar 29. PMID: 33780932.
75. **Bezzio C**, Andreozzi P, Casini V, Manes G, Saibeni S. Endoscopy for patients affected by inflammatory bowel disease: bowel preparation and sedation. *Expert Rev Gastroenterol Hepatol*. 2018;12:119-124.
76. **Bezzio C**, Bryant RV, Manes G, Maconi G, Saibeni S. New horizons in the imaging of perianal Crohn's disease: transperineal ultrasonography. *Expert Rev Gastroenterol Hepatol*. 2017;11:523-530.
77. **Bezzio C**, Festa S, Saibeni S, Papi C. Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence. *Expert Rev Gastroenterol Hepatol*. 2017;1:339-347. doi: 10.1080/17474124.2017.1292129. Epub 2017 Feb 16.
78. Viganò C, Calzolari R, Marinaccio PM, **Bezzio C**, Furfaro F, Ba G, Maconi G. Unrevealed Depression Involves Dysfunctional Coping Strategies in Crohn's Disease Patients in Clinical Remission. *Gastroenterol Res Pract*. 2016;2016:7803262. doi: 10.1155/2016/7803262. Epub 2015 Dec 28. PMID: 26823663; PMCID: PMC4707369.
79. **Bezzio C**, Furfaro F, de Franchis R, Maconi G, Asthana AK, Ardizzone S. Ulcerative colitis: current pharmacotherapy and future directions. *Expert Opin Pharmacother*. 2014;15:1659-70.
80. Manes G, Andreozzi P, Omazzi B, **Bezzio C**, Redaelli D, Devani M, Morganti D, Reati R, Saibeni S, Mandelli E, Arena I, Hassan C, de Nucci G. Efficacy of withdrawal time monitoring in adenoma detection with or without the aid of a full-spectrum scope. *Endosc Int Open*. 2019;7:E1135-E1142.
81. Furfaro F, **Bezzio C**, Ardizzone S, Massari A, de Franchis R, Maconi G. Overview of biological therapy in ulcerative colitis: current and future directions. *J Gastrointest Liver Dis*. 2015 Jun;24(2):203-13.
82. Maconi G, Furfaro F, Sciurti R, **Bezzio C**, Ardizzone S, de Franchis R. Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications. *World J Gastroenterol*. 2014 7;20:3507-15.
83. **Bezzio C**, Imperatore N, Armuzzi A, Rizzello F, Manes G, Bossa F, Calabrese E, Caprioli F, Daperno M, Mocchiari F, Orlando A, Papi C, Rispo A, Saibeni S; Italian Group for Inflammatory Bowel Disease (IG-IBD). Unmet needs of Italian physicians managing patients with inflammatory bowel disease. *Dig Liver Dis*. 2019;51:212-217.
84. **Bezzio C**, Fasci-Spurio F, Viganò C, Meucci G, Papi C, Saibeni S. The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology. *Expert Rev Gastroenterol Hepatol*. 2017 Jan;11(1):33-41.
85. Andreozzi P, De Nucci G, **Bezzio C**, Arena I, Devani M, Mandelli E, Morganti D, Omazzi B, Reati R, Redaelli D, Saibeni S, Manes G. Comparison of asymmetric (low morning-dose) and standard split-dose regimen of PEG plus bisacodyl for bowel preparation: A randomized controlled trial. *Dig Liver Dis*. 2019;51:837-842.
86. Defendenti C, Atzeni F, Malandrini S, Ardizzone S, Almasio PL, Saibeni S, **Bezzio C**, Bollani S, Salerno R, Declich P, Sarno Z, Bruno S, Talotta R, Sarzi-Puttini P. Anti-tumour necrosis factor- $\alpha$  antibodies and B cell homeostasis in human inflammatory bowel diseases. *Int Immunopharmacol*. 2018;54:329-335.

87. **Bezzio C**, Arena I, Devani M, Omazzi B, Manes G, Saibeni S. Aspecific ileitis: Crohn's disease or not Crohn's disease? A prospective study. *Int J Colorectal Dis.* 2017 32:1025-1028..
88. Maconi G, Furfaro F, Fries W, Dell'Era A, **Bezzio C**, Costantino G, Giuliano V, Alibrandi A, Guzowski T, Bassotti G. Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. *Liver Int.* 2017 Jan;37:141-147.
89. Viganò C, Calzolari R, Marinaccio PM, **Bezzio C**, Furfaro F, Ba G, Maconi G. Unrevealed Depression Involves Dysfunctional Coping Strategies in Crohn's Disease Patients in Clinical Remission. *Gastroenterol Res Pract.* 2016;2016:7803262.
90. Maconi G, Lombardini M, Furfaro F, **Bezzio C**, Zerbi P, Ardizzone S. Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment. *Eur J Gastroenterol Hepatol.* 2014;26:1146-51.
91. Mantegazza C, Maconi G, Giacomet V, Furfaro F, Mameli C, **Bezzio C**, Monteleone M, Ramponi G, Zuccotti GV. Gut and mesenteric lymph node involvement in pediatric patients infected with human immunodeficiency virus. *HIV AIDS .* 2014 8;6:69-74
92. Maconi G, Tonolini M, Monteleone M, **Bezzio C**, Furfaro F, Villa C, Campari A, Dell'Era A, Sampietro G, Ardizzone S, de Franchis R. Transperineal perineal ultrasound versus magnetic resonance imaging in the assessment of perianal Crohn's disease. *Inflamm Bowel Dis.* 2013;19:2737-43.
93. Cantù P, **Bezzio C**. Role of a short-term stent-trial in a patient with biliary stricture and portal hypertensive biliopathy: long-term outcome result. *Dig Dis Sci.* 2011;56:1242-4.
94. Maconi G, Monteleone M, Furfaro F, **Bezzio C**, Tonolini M, Sampietro G. Abdominal pain after minor trauma in a patient with Crohn's disease. *J Gastrointestin Liver Dis.* 2013;22:361-2.
95. Maconi G, Asthana AK, Bolzacchini E, Dell'Era A, Furfaro F, **Bezzio C**, Salvatore V, Maier JA. Splanchnic Hemodynamics and Intestinal Vascularity in Crohn's Disease: An In Vivo Evaluation Using Doppler and Contrast-Enhanced Ultrasound and Biochemical Parameters. *Ultrasound Med Biol.* 2016;42:150-8.
96. Maconi G, Radice E, Greco S, **Bezzio C**, Bianchi Porro G. Transient small-bowel intussusceptions in adults: significance of ultrasonographic detection. *Clin Radiol.* 2007;62:792-7.
97. Maconi G, Orlandini L, Asthana AK, Sciurti R, Furfaro F, **Bezzio C**, de Franchis R. The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn's disease: A prospective study. *Dig Liver Dis.* 2015;47:646-51
98. Maconi G, Ardizzone S, Cucino C, **Bezzio C**, Russo AG, Bianchi Porro G. Pre-illness changes in dietary habits and diet as a risk factor for inflammatory bowel disease: a case-control study. *World J Gastroenterol.* 2010 14;16:4297-304.
99. Maconi G, Ardizzone S, Greco S, Radice E, **Bezzio C**, Bianchi Porro G. Transperineal ultrasound in the detection of perianal and rectovaginal fistulae in Crohn's disease. *Am J Gastroenterol.* 2007;102:2214-9.

Milan, September 4 th, 2024

